Xencor (XNCR) Stock Forecast & Price Target

Xencor is viewed positively because its XmAb platform has already validated engineered antibody innovation and now offers multiple near-term catalysts across oncology and immunology, with XmAb819 standing out as the most important rerating driver. The company’s 2Q26 results also improved the fundamental backdrop, as EPS of $(0.29) beat the $(0.83) expectation, U.S. Ultomiris royalty revenue returned at $27.6M, and a $10M Zenas milestone helped lift YE26 cash guidance to $420–440MM with runway through 2028. In addition, XmAb819’s potential to hold about 25% ORR with >6-mo mPFS and manageable CRS in heavily pretreated ccRCC, alongside XmAb942’s early de-risking and multiple 2H26 updates, supports a favorable risk/reward profile.

Xencor is viewed negatively because its value depends heavily on a narrow set of clinical readouts, and XmAb819 still faces major uncertainty around durability even after showing 25% ORR and 70% DCR in 20 target-dose patients. While safety has been manageable, the prior CRS issues tied to priming-dose preparation errors highlight execution risk, and the company’s broader pipeline remains exposed to the inherent unpredictability of oncology and autoimmune trials. Financially, it relies on collaboration and licensing revenue, needs additional capital before commercialization, and faces dilution, regulatory, competitive, and partnership risks that can pressure returns if the planned 2027 registrational study is not meaningfully de-risked.